A detailed history of Cetera Investment Advisers transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Cetera Investment Advisers holds 132,000 shares of AUTL stock, worth $287,760. This represents 0.0% of its overall portfolio holdings.

Number of Shares
132,000
Previous 134,500 1.86%
Holding current value
$287,760
Previous $468,000 2.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.38 - $4.69 $8,450 - $11,725
-2,500 Reduced 1.86%
132,000 $479,000
Q2 2024

Aug 22, 2024

BUY
$3.33 - $5.68 $9,054 - $15,443
2,719 Added 2.06%
134,500 $468,000
Q1 2024

May 24, 2024

BUY
$5.39 - $7.29 $710,299 - $960,683
131,781 New
131,781 $840,000
Q4 2023

Feb 13, 2024

SELL
$2.13 - $6.63 $5,325 - $16,575
-2,500 Reduced 1.87%
131,500 $846,000
Q3 2023

Nov 14, 2023

SELL
$2.32 - $3.36 $2,784 - $4,032
-1,200 Reduced 0.89%
134,000 $312,000
Q2 2023

Aug 09, 2023

SELL
$1.64 - $3.21 $10,496 - $20,544
-6,400 Reduced 4.52%
135,200 $321,000
Q1 2023

May 15, 2023

BUY
$1.75 - $2.25 $7,000 - $9,000
4,000 Added 2.91%
141,600 $260,000
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $3,828 - $7,194
2,200 Added 1.62%
137,600 $261,000
Q3 2022

Nov 10, 2022

BUY
$2.04 - $3.76 $17,136 - $31,584
8,400 Added 6.61%
135,400 $290,000
Q2 2022

Aug 11, 2022

BUY
$2.04 - $4.68 $5,508 - $12,636
2,700 Added 2.17%
127,000 $359,000
Q1 2022

May 13, 2022

BUY
$3.52 - $5.46 $33,616 - $52,143
9,550 Added 8.32%
124,300 $518,000
Q4 2021

Feb 14, 2022

BUY
$5.1 - $7.0 $49,215 - $67,550
9,650 Added 9.18%
114,750 $596,000
Q3 2021

Nov 16, 2021

BUY
$5.32 - $7.37 $559,132 - $774,587
105,100 New
105,100 $688,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $198M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.